Invitae (NVTAQ) Stock Price
Invitae Price
Over the last 10 years Invitae grew revenue by 124.8% annually, reaching 487.00 M USD. For Invitae, the net margin of -295.8% is down versus -111.6% a few years ago.
Invitae stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Invitae over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Invitae stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Invitae's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Invitae Price |
|---|
Invitae Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Invitae Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | 1.00 | 8.00 | 25.00 | 68.00 | 147.00 | 216.00 | 279.00 | 460.00 | 516.00 | 487.00 | 476.00 | 592.00 | 614.00 |
| – | – | – | 700.00 | 212.50 | 172.00 | 116.18 | 46.94 | 29.17 | 64.87 | 12.17 | -5.62 | -2.26 | 24.37 | 3.72 |
| – | – | -400.00 | -100.00 | -8.00 | 26.47 | 45.58 | 45.37 | 27.24 | 23.70 | 19.19 | 51.75 | 51.75 | 51.75 | 51.75 |
| 252.00 | 252.00 | -4.00 | -8.00 | -2.00 | 18.00 | 67.00 | 98.00 | 76.00 | 109.00 | 99.00 | 252.00 | 246.31 | 306.33 | 317.72 |
| -8.00 | -24.00 | -47.00 | -89.00 | -106.00 | -130.00 | -125.00 | -248.00 | -629.00 | -661.00 | -704.00 | 175.00 | -307.00 | -302.00 | -265.00 |
| – | – | -4,700.00 | -1,112.50 | -424.00 | -191.18 | -85.03 | -114.81 | -225.45 | -143.70 | -136.43 | 35.93 | -64.50 | -51.01 | -43.16 |
| -0.01 | -0.02 | -0.05 | -0.09 | -0.10 | -0.12 | -0.13 | -0.24 | -0.60 | -0.38 | -3.11 | -1.44 | – | -0.22 | -0.25 |
| – | 200.00 | 95.83 | 89.36 | 12.36 | 23.00 | 4.88 | 86.82 | 149.79 | -37.04 | 719.53 | -53.64 | – | – | 12.27 |
| 1.00 | 14.88 | 29.80 | 31.93 | 36.25 | 52.02 | 75.09 | 97.37 | 179.86 | 226.85 | 243.95 | 275.60 | 275.60 | 275.60 | 275.60 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Invitae generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Invitae retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Invitae's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Invitae has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Invitae's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Invitae stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Invitae Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Invitae business model & stock analysis
Invitae SWOT Analysis
Strengths
Invitae Corp possesses several strengths that contribute to its success:
- Wide Range of Genetic Testing: Invitae offers a comprehensive portfolio of genetic tests, catering to various medical conditions and diseases.
- Advanced Technology: The company utilizes cutting-edge technology for accurate and reliable genetic testing results.
- Strong Partnerships: Invitae has established strategic partnerships with leading healthcare providers and pharmaceutical companies.
- Growing Customer Base: The company has witnessed significant growth in its customer base, indicating strong market demand for genetic testing services.
Weaknesses
Despite its strengths, Invitae Corp also faces certain weaknesses:
- Pricing Challenges: Genetic testing services can be expensive, which may limit the accessibility for some potential customers.
- Intense Competition: The genetic testing market is highly competitive, with numerous companies vying for market share.
- Regulatory Compliance: The company needs to comply with stringent regulations governing genetic testing, increasing operational complexities.
Opportunities
Invitae Corp can capitalize on the following opportunities:
- Market Expansion: The increasing awareness and adoption of genetic testing present opportunities for Invitae to expand its market presence.
- Technological Advancements: Advancements in genetic research and technology may create new testing opportunities for the company.
- Collaborations and Partnerships: Forming strategic collaborations and partnerships can help Invitae tap into new customer segments and markets.
Threats
Invitae Corp should be cautious about the following threats:
- Regulatory Risks: Changes in regulations and policies governing genetic testing may impact the company's operations and financials.
- New Entrants: The entry of new competitors in the genetic testing market can intensify competition and challenge Invitae's market position.
- Data Privacy Concerns: Maintaining data privacy and ensuring compliance with privacy regulations are critical, given the sensitive nature of genetic information.
Invitae Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Invitae historical P/E ratio, EBIT multiple, and P/S ratio
Invitae annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Invitae shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Invitae Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 11/13/2023 | Maintained | Underweight | 51 | |
| 10/23/2023 | Maintained | Sell | – | |
| 10/20/2023 | Maintained | Sell | – | |
| 8/15/2023 | Maintained | Underweight | 51 | |
| 7/24/2023 | Maintained | Sell | – | |
| 7/21/2023 | Maintained | Sell | – | |
| 5/15/2023 | Downgrade | Market PerformUnderperform | 74 | |
| 5/11/2023 | Maintained | Sell | – | |
| 3/3/2023 | Maintained | Underweight | 51 | |
| 1/31/2023 | Downgrade | NeutralSell | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Invitae Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/6/2024 | -0.21USD | - | 126.90 MUSD | - | 2024 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Invitae stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Invitae shareholder structure
| % | Name |
|---|---|
0.08224% | |
0.02445% | |
0.01257% | |
0.00985% | |
0.00349% | |
0.00349% |
Invitae Beneficial Ownership Filings (SEC 13D/G)
Invitae Executives and Management Board
16 members · avg. age 58 · 31 % women
Mr. Kenneth Knight (62)
President, Chief Executive Officer, Director · since 2020
4.95 M USD
Management
Mr. Thomas Brida (52)
Chief Compliance Officer, General Counsel, Secretary
Dr. Robert Nussbaum (73)
Chief Medical Officer
Ms. Ana Schrank (57)
Chief Financial Officer, Chief Accounting Officer
Dr. David Sholehvar (56)
Chief Operating Officer
Mr. Veteran Robert Guigley
Chief Commercial Officer
Dr. W. Michael Korn
Chief Medical Officer - Oncology
Board of Directors
Dr. Sean George (49)
Director · since 2010
Dr. Eric Aguiar (61)
Lead Independent Director
Ms. Christine Gorjanc (66)
Director · since 2015
Mr. Geoffrey Crouse (52)
Independent Director
Ms. Kimber Lockhart (36)
Independent Director
Ms. Chitra Nayak (60)
Independent Director
Frequently asked questions about Invitae
The business model of Invitae Corp is focused on providing comprehensive genetic information to guide healthcare decisions. Invitae offers genetic testing services, including diagnostic testing for hereditary diseases and disorders, as well as proactive testing for healthy individuals. The company's goal is to make genetic information accessible and affordable, enabling personalized healthcare and aiding in clinical research. Invitae utilizes advanced technologies and a scalable platform to deliver high-quality, cost-effective genetic testing solutions. By empowering patients, physicians, and researchers with genetic insights, Invitae aims to improve the understanding, treatment, and prevention of genetic diseases.
Invitae Corp is primarily active in the healthcare and biotechnology industries.
Invitae Corp's main competitors in the market include other genetic testing companies such as Myriad Genetics, Exact Sciences, and Natera.
Invitae Corp is a leading medical genetics company based in San Francisco, California. Founded in 2010, Invitae is focused on providing genetic information to empower patients and healthcare providers in making informed medical decisions. With a mission to bring comprehensive genetic information into mainstream medical practice, Invitae offers a wide range of genetic tests across various medical specialties. The company has rapidly grown through strategic acquisitions and partnerships, expanding its portfolio and capabilities. Invitae's commitment to innovative genetic testing solutions and its dedication to improving patient outcomes has made it a trusted name in the field of medical genetics.
Invitae Corp has achieved several significant milestones in its journey. The company successfully completed several strategic acquisitions, such as CombiMatrix, Good Start Genetics, and Clear Genetics, which have expanded their genetic testing offerings. Invitae Corp also established numerous partnerships with prominent organizations, including Biogen, Bristol Myers Squibb, and Genome Medical, to advance precision medicine research and development. Additionally, they launched a groundbreaking genetic testing platform, enabling fast and affordable genetic testing solutions. Invitae Corp's accomplishments signify their commitment to revolutionizing genetic testing and personalized medicine, positioning them as a key player in the industry.
Invitae Corp is primarily present in the United States.
Invitae Corp is guided by a set of core values and a strong corporate philosophy. The company is committed to providing high-quality genetic information to individuals, families, and healthcare providers. With a focus on patients and their needs, Invitae Corp aims to make genetic testing more accessible and affordable. They strive to deliver accurate results and ensure the information is understandable and actionable for all stakeholders. Invitae Corp also emphasizes collaboration and partnerships within the medical community to advance genetic knowledge and improve patient care. Through these values and their dedication to genetic information, Invitae Corp strives to empower people with the insights to make informed healthcare decisions.
15 analysts currently rate the Invitae stock: 0 recommend buying, 6 holding and 9 selling. For 2026, analysts expect Invitae to generate revenue of 614.60 M USD and earnings per share of -0.90 USD.
Converted at the current exchange rate, the Invitae share trades at 0.00 EUR (0.00 USD).
The Invitae share (NVTAQ) is listed on 7 stock exchanges, including: NYSE (NVTA), Frankfurt (IV8.F), München (IV8.MU), Düsseldorf (IV8.DU), London (0JDB.L), London (0JDB.L), SIX (Zürich) (IV8.SW).
Invitae Corp is a company specialized in providing genetic tests. Its business model consists of offering customers accurate insights into their DNA and helping them identify genetic risks or predispositions in order to make better health-related decisions. The company has a specialized laboratory that performs and analyzes genetic tests. Invitae conducts tests in various areas, such as oncology, neurology, and rare diseases. The company also offers a wide range of tests, ranging from preventive screenings to targeted diagnostic tests. To offer these tests, Invitae has built a platform that makes it easy to order genetic tests. Customers can order a test directly from home without needing a referral from a doctor. Patients can order either directly through Invitae's website or through a doctor if they prefer. The company also offers various products such as the "Invitae Carrier Screening," which investigates the transmission of genetic diseases from parents to their children. These tests can also help identify couples at high risk, optimize their genetic counseling, and assist them in family planning. Invitae also provides solutions for customers who have already undergone genetic tests and want to have their results analyzed. The company has developed specialized services that allow combining the results of different tests to provide customers with a comprehensive range of information. The company also partners with various companies and organizations to promote and sell its products and services. Its partners include major hospital systems, laboratories, and insurance companies. Invitae Corp focuses on offering genetic tests in multiple areas to maximize the benefits of genetic technology for patients. It has built an e-commerce platform that makes it easy for customers to order its products. Invitae also offers a wide range of tests covering various applications. With its innovative and comprehensive services, Invitae Corp has established itself as a leading company in the genetics industry.
The expected revenue of Invitae is 614.60 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Invitae is -247.87 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Invitae is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Invitae stock.
The price-to-sales ratio (P/S) of Invitae is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Invitae stock.
The Eulerpool Quality Score for Invitae is 6/10.
The ISIN of Invitae is US46185L1035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Invitae is A14NKG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Invitae is NVTAQ. The ticker symbol is used to trade Invitae shares on the stock exchange.
Invitae paid dividends every year for the past 0 years.
Invitae is assigned to the 'Health' sector.
The dividends of Invitae are distributed in USD.
Invitae stock
Invitae Peer Group
Invitae Ticker
Invitae FIGI
All fundamentals and in-depth analysis of Invitae
Our stock analysis for Invitae stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Invitae. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.